The project, coordinated by Jena University Hospital and expected to run for five years, aims to address resistance mechanisms in Gram-negative pathogens.
Funding for Fluidigm's assay through NIH's RADx program was increased by approximately $22 million for a total contract value of up to about $34 million.
Applied DNA Sciences previously partnered with Stony Brook University Hospital to validate the test, which received Emergency Use Authorization in May.
The PCR assay is used for the detection of SARS-CoV-2 RNA in anterior nasal swab specimens self-collected at home using the Vo' COVID-19 Test Home Collection Kit.
BillionToOne's assay detects SARS-CoV-2 in samples from nasal, nasopharyngeal, and oropharyngeal swabs and has a testing capacity of 1 million tests per day.
Sema4 will use its genomics testing abilities and Centrellis health intelligence platform to identify eligible patients for Janssen's oncology clinical trials.
Whole-exome sequencing of 250 parent-offspring trios provided evidence for genetically mediated dysregulation of early neuronal connectivity in cerebral palsy.
The study, involving almost 1.8 million individuals, further found only modest overlap between the genetic underpinnings of left-handedness and ambidexterity.
Investigators identified disease-associated histone modifications in the brain that appeared to influence transcription- and chromatin-related processes.
The firm's Nanotrap virus particles provide an alternative to RNA extraction kits and could help improve detection for respiratory viruses, including SARS-CoV-2.
The submission data highlights Parsortix's ability to harvest circulating tumor cells from metastatic breast cancer patient blood samples for downstream analysis.
The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.
The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.
The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.
